Carrageenan
Based on 1 publication(s) in Google Scholar
Carrageenan is an antiviral and anticancer agent. Carrageenan inhibits herpes simplex virus (HSV), HIV, and hepatitis A virus (HAV) by directly binding to the viral capsid to block the attachment of viruses such as HPV to HSPG factors on the cell surface. Carrageenan delays and arrests cell cycle progression, exhibits cytotoxicity against HeLa cancer cells, and can be applied to studies related to cervical cancer, genital warts, hepatitis A, and other conditions. Carrageenan also induces acute non-immune inflammation, triggers a three-phase inflammatory response involving the release of multiple proinflammatory mediators, and causes persistent edema, hyperalgesia, and neutrophil recruitment in mice.
For research use only. We do not sell to patients.
- CAS No.: 9000-07-1
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Carrageenan
More
Biological Activity
Description
In Vitro
ι-carrageenan (HY-W145523), λ-carrageenan (HY-N9470) and κ-carrageenan (HY-138962) (20-1000 μg/mL; 3-15 d) show no significant cytotoxicity against PLC/PRF/5 cells at concentrations up to 200 μg/mL. Among them, the cytotoxicity thresholds (cell viability CD50 >1000 μg/mL) of ι-carrageenan and λ-carrageenan are higher than that of κ-carrageenan (cell viability CD50=732.1 μg/mL)[2].
ι-carrageenan, λ-carrageenan, and κ-carrageenan (0.5-200 μg/mL; 15 d) potently inhibit the expression of HAV antigen in PLC/PRF/5 cells in a concentration-dependent manner in vitro, among which ι-carrageenan (ED50=2.5 μg/mL) exhibits the strongest activity, followed by λ-carrageenan (ED50=4.5 μg/mL) and κ-carrageenan (ED50=100.3 μg/mL); meanwhile, they also reduce the replication and infectivity of HAV in PLC/PRF/5 cells in a concentration-dependent manner[2].
κ-carrageenan and λ-carrageenan (250-2500 μg/mL; 72 h) exhibit moderate concentration-dependent cytotoxicity against HeLa cells, with λ-carrageenan (IC50=475 μg/mL) showing stronger activity than κ-carrageenan (IC50=550.8 μg/mL); in addition, λ-carrageenan also exerts a strong concentration-dependent antiproliferative effect and reduces cell confluence[3].
κ-carrageenan (250-2500 μg/mL; 72 h) induces concentration-dependent G2/M phase arrest in HeLa-FUCCI cells, whereas λ-CO does not alter the proportion of each cell cycle phase in HeLa-FUCCI cells[3].
κ-carrageenan and λ-carrageenan (250-2500 μg/mL; 72 h) show no significant cytotoxicity against HUVEC at concentrations up to 2500 μg/mL, and do not increase the mortality of HUVEC cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HeLa
-
Concentration:250-2500 μg/mL
-
Incubation Time:72 h
-
Result:Increased dead cell percentage in a dose-dependent manner (k-CO).
Increased dead cell percentage in a dose-dependent manner and reduced cell confluence in a concentration-dependent manner (λ-CO).
-
Cell Line:HeLa-FUCCI
-
Concentration:250-2500 μg/mL
-
Incubation Time:72 h
-
Result:Caused a concentration-dependent increase in the ratio of cells arrested in the G2/M phase, with a linear correlation between concentration and G2/M phase cell ratio (k-CO).
Showed no significant difference in cell cycle phase ratios compared to untreated cells (λ-CO).
In Vivo
Carrageenan (1% (w/v); s.c.; plantar region of the left hind paw) at an injection volume of 100 μL induces acute paw edema in male Wistar rats (with the peak edema volume reached 4-5 hours post-injection), while an injection volume of 25 μL induces acute paw edema in male Swiss albino mice[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss mice (male, 30-35 g); C57/BL6 mice (male, 30-35 g); TNF-α p55 receptor knockout mice (C57/BL6 background, male, 30-35 g)[4]
-
Dosage:300 μg per paw
-
Administration:s.c.; single injection
-
Result:Induced a biphasic paw oedema (peaks at 6 and 72 hours) in Swiss and C57/BL6 mice, which resolved by 96 hours.\n
Caused sustained mechanical allodynia, detectable as early as 1 hour post-injection and persisting for up to 72 hours, with similar response frequencies in Swiss and C57/BL6 mice.\n
Increased MPO activity in paw tissue by ~10-fold at 6 hours post-injection in Swiss and C57/BL6 mice.\nReduced paw oedema by 89% at 6 hours and 50% at 48 hours in TNF-α p55 receptor knockout mice.\n
Reduced mechanical allodynia by 39% at 6 hours, 37% at 24 hours, and 25% at 48 hours in TNF-α p55 receptor knockout mice.\n
Reduced MPO activity by 51% at 6 hours in TNF-α p55 receptor knockout mice.
-
Animal Model:Wistar (male, 165-220 g) and Albino Swiss (male, 25-35 g)[5]
-
Dosage:100 μL of 1% (w/v), 25 μL of 1% (w/v)
-
Administration:s.c. into plantar region of left hind paw; single dose
-
Result:Induced acute paw edema, with paw volume increasing to a maximum of ~2.2 mL at 4-5 hours post-injection, then decreasing to ~1.8 mL by 24 hours post-injection.
Induced acute paw edema, with plethysmometry used to quantify volume changes over the 24-hour period.
Chemical Information
-
CAS No. 9000-07-1
-
Appearance Solid
-
Color White to off-white
-
SMILES
[Carrageenan]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Inflammopharmacology
The sesquiterpene lactone components of Cichorium glandulosum suppress both in vitro and in vivo inflammatory responses by reducing IL-1β levels. [Abstract]2025 Dec 2. PMID: 41329398
Solvent & Solubility
In Vitro:
H2O : 3.33 mg/mL (ultrasonic and warming and heat to 60°C)
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Zymosan-Induced Peritonitis
Zymosan-induced peritonitis is a sterile acute-inflammation model produced by intraperitoneal injection of zymosan, a yeast cell-wall particle preparation, followed by quantification of leukocyte recruitment and soluble inflammatory mediators in peritoneal lavage fluid. Low-dose zymosan peritonitis is commonly used as a self-resolving acute inflammation model in which neutrophil recruitment occurs early and monocyte/macrophage accumulation follows later. The assay readouts include total peritoneal leukocyte number, differential neutrophil and monocyte/macrophage counts, peritoneal cytokines and chemokines, plasma or peritoneal exudation, and optional lipidomic or metabolomic changes during inflammation and resolution. Early neutrophil recruitment after zymosan depends strongly on complement and mast-cell C5a receptor signaling, whereas later monocyte recruitment is linked to MCP-1/CCL2 production.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Buck CB, et al. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2006;2(7):e69. [Content Brief]
[2]. Girond S, et al. Antiviral activity of carrageenan on hepatitis A virus replication in cell culture. Res Virol. 1991;142(4):261-270. [Content Brief]
[3]. Prasedya ES, et al. Carrageenan delays cell cycle progression in human cancer cells in vitro demonstrated by FUCCI imaging. BMC Complement Altern Med. 2016;16:270. Published 2016 Aug 4. [Content Brief]
[4]. Rocha AC, et al. Relevance of tumour necrosis factor-alpha for the inflammatory and nociceptive responses evoked by carrageenan in the mouse paw. Br J Pharmacol. 2006;148(5):688-695. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)